2.3 Cardiac Transplant

2.3 Cardiac Transplant

Quick Answer: Pediatric heart transplantation is offered when myocardial failure or anatomy cannot be rehabilitated—commonly dilated cardiomyopathy and failing single-ventricle circulation. Post-transplant PICU care centers on graft systolic/diastolic function, pulmonary vascular resistance facing the donor right ventricle, rejection surveillance, timed immunosuppression with drug-level stewardship, and aggressive infection prevention because fever and inflammatory signs may be muted.

Indications and Listing Context

Heart transplant is considered when survival and quality of life with native heart options are unacceptable. High-yield pediatric indications include:

• Dilated cardiomyopathy refractory to medical therapy and unable to wean from inotropes/VAD support
• Restrictive or hypertrophic cardiomyopathy with end-stage diastolic failure or ischemia/arrhythmia risk not amenable to other surgery
• Failed or failing single-ventricle palliation (e.g., protein-losing enteropathy, plastic bronchitis, systemic ventricular failure after Fontan)
• Complex congenital heart disease without a durable surgical pathway
• Selected unresectable cardiac tumors or irreversible graft failure after prior transplant (retransplant)

Contraindications are center-specific but conceptually include irreversible elevated PVR beyond what a donor right ventricle can face, active uncontrolled infection, and social/adherence barriers that make lifelong immunosuppression unsafe. Mechanical circulatory support (VAD/ECMO) is often a bridge; nursing continuity from bridge to transplant includes device alarms, anticoagulation, and infection control that carry into the post-transplant phase.

Early Postoperative Graft Care

The transplanted heart is denervated. Resting heart rate is often higher; atropine will not reliably increase rate because vagal innervation is absent. Bradycardia and AV block are treated with isoprotenerol, epinephrine, pacing, or other direct-acting chronotropes per protocol—not relying on vagolytic drugs.

Immediate PICU priorities

Strategies that lower PVR—adequate oxygenation, avoidance of acidosis and hypercarbia extremes, sedation, inhaled nitric oxide when indicated—protect the donor RV. Volume loading must be thoughtful: the denervated, ischemic-reperfusion–stressed myocardium may not tolerate overdistension.

Rejection Surveillance

Rejection remains a leading threat to graft survival. Categories include cellular rejection and antibody-mediated rejection; exam questions emphasize recognition and nursing response, not histologic grading minutiae.

Clinical and monitoring clues:

• New or worsening heart failure signs: tachycardia beyond baseline denervated rate, gallop, edema, hepatomegaly, feeding intolerance
• Arrhythmias or unexplained low cardiac output
• Echo: reduced ejection fraction, increased wall thickness, new effusion, diastolic dysfunction
• Endomyocardial biopsy (scheduled or for-cause) and center-specific noninvasive gene-expression or donor-derived cell-free DNA assays

Nursing role: know the surveillance calendar, protect vascular access for biopsy, watch for post-biopsy complications (tamponade, tricuspid injury, arrhythmia), and escalate subtle perfusion changes rather than waiting for frank shock. Intensified immunosuppression for treated rejection raises infection and drug-toxicity risk—plan isolation and lab monitoring accordingly.

Immunosuppression Nursing

Typical multidrug regimens combine:

1. Calcineurin inhibitor (tacrolimus or cyclosporine) — nephrotoxicity, tremor, hypertension, drug interactions via CYP3A4
2. Antiproliferative agent (mycophenolate or azathioprine) — marrow suppression, GI intolerance
3. Corticosteroids — hyperglycemia, wound healing delay, hypertension, mood changes; tapered when possible
4. Induction agents (ATG, basiliximab, etc.) in many pediatric protocols — profound early lymphodepletion and infection risk

Nursing non-negotiables:

• Administer on schedule; hold parameters only with explicit transplant-team orders tied to trough levels
• Draw troughs correctly timed before doses
• Screen for interactions (azole antifungals, macrolides, certain anticonvulsants, grapefruit) that spike or crash calcineurin levels
• Monitor renal function, CBC, glucose, magnesium, and blood pressure
• Educate caregivers early: lifelong adherence prevents late rejection

Never start nephrotoxic or interacting antimicrobials without transplant pharmacy/team clearance.

Infection Risk

Immunosuppression creates a timed vulnerability curve:

Fever may be absent or blunted. Tachycardia, feeding refusal, irritability, rising CRP/procalcitonin, or graft dysfunction can be infection’s first face. CMV disease can present with cytopenias, hepatitis, pneumonitis, or graft dysfunction—know whether the recipient is D+/R− high risk. Strict visitor screening during RSV/influenza seasons protects both graft and child.

Integrating Structure, Surgery, and Transplant on the Exam

Cardiac malformations explain why a child reaches transplant listing; surgery and catheterization chapters explain bridges and complications along the way; transplant content tests whether you can manage a denervated graft under immunosuppression. When a stem mentions Fontan failure, VAD bridge, or primary graft dysfunction, return to perfusion markers, PVR, rejection versus infection differentiation, and drug-level stewardship.

Practical CCRN framing: If the child is blue and ductal-dependent, think PGE1 and mixing. If the child is post-shunt, think Qp:Qs and thrombosis. If the child is post-switch, think coronaries. If the child is post-transplant, think graft function, denervation pharmacology, rejection surveillance, and infection—often simultaneously.